The short version
7 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Tavaborole
Tavaborole · TAVABOROLE 43.5 mg/mL · Solution · Topical · Amneal Pharmaceuticals NY LLC
NDC 69238-1657-04 · 1 BOTTLE, WITH APPLICATOR in 1 CARTON / 4 mL in 1 BOTTLE, WITH APPLICATOR · ANDA · View full market →
One drug, every price
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
ⓘ How this was built
Data sources
- CMS NADAC (pharmacy acquisition, weekly)
- CMS Part B ASP quarterly payment limits
- CMS Maximum Fair Prices (IRA negotiated, NDC-level)
- Medicare Part D Spending by Drug (data.cms.gov, name-matched)
- VA FSS / Big4 federal contract prices (va.gov, twice monthly)
- ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
- California SB-17 WAC filings (list price, per package)
Method
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
- Part D plans paid (avg)$50.71per dosage unitgross, before rebates — matched by drug name · 2024
- Medicaid generic ceiling (FUL)$5.37per MLweighted avg manufacturer price $1.6702 · Nov 1, 2023
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$315.25
Reported to Texas DSHS · 2023 annual filing · Amneal Pharmaceuticals LLC
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicaid spend (2022)
$3,955
60 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for tavaborole (other) in the next 90 days
sole-source market · 1 Class I/II recall(s) in 12 months
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Regulatory
- Application
- ANDA212256
- TE code
- —
- Approval date
- Nov 25, 2020
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Tavaborole (Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Alembic Pharmaceuticals Inc. | TAVABOROLE 43.5 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Alembic Pharmaceuticals Limited | TAVABOROLE 43.5 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Amneal Pharmaceuticals NY LLC | TAVABOROLE 43.5 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Chartwell RX, LLC | TAVABOROLE 43.5 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Cipla USA Inc. | TAVABOROLE 43.5 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Viona Pharmaceuticals Inc | TAVABOROLE 43.5 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Lifesciences Limited | TAVABOROLE 43.5 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Tavaborole — NDC 69238-1657-04," retrieved September 3, 2026, https://drugdashboards.com/drug/69238165704.
Free to cite with attribution — see how the data is put together.